15 Best Biotech Stocks to Buy According to Billionaires

Page 4 of 13

10. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

Number of Billionaires: 13 

Dollar Value of Billionaire Holdings: $1,356,633,560 

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is a clinical-stage biopharmaceutical company focused on developing therapies for liver and metabolic diseases, particularly nonalcoholic steatohepatitis (NASH). Its lead drug, resmetirom, targets thyroid hormone receptor beta (THR-β) and has shown promising results in reducing liver fat by 48% in clinical trials.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) reported strong sales growth for Q4 2024, with net sales reaching $103.3 million, a 66% increase from the previous quarter. For the full year 2024, the company achieved $180.1 million in sales, which was primarily driven by the successful launch of its drug Rezdiffra. By the end of Q4, over 11,800 patients were using the drug. Despite the strong sales, the business’s R&D expenses decreased to $25.6 million for Q4, reflecting improved efficiency, while SG&A expenses rose to $141.2 million due to investments in commercial infrastructure. The company ended 2024 with a solid cash position of $931.3 million.

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)’s growth is attributed to the rapid adoption of Rezdiffra, with the 66% quarter-over-quarter increase suggesting strong market penetration. Additionally, Rezdiffra’s inclusion in updated treatment guidelines by leading liver societies in Europe and the US further supports its clinical value and adoption in the healthcare community.

Page 4 of 13